© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
March 02, 2021
The FDA is currently reviewing the results of these trials and is scheduled to make an approval decision by May 28, 2021.
February 25, 2021
The outcome of the Decipher Prostate test was independently associated with overall survival, prostate cancer–specific mortality, and risk of metastasis.
“I find [the Prolaris test] to be a very helpful clinical tool,” says Jonathan D. Tward, MD, PhD.
February 24, 2021
Hear from key opinion leaders in the urology space as they discuss 2 complex cases across the multidisciplinary approach for an incidentally discovered adrenal mass and localized, high-risk prostate cancer with oligometastasis at diagnosis.
February 22, 2021
Abiraterone/prednisone can increase survival in prostate cancer; however, most patients develop resistance between 9 and 16 months after starting treatment.
February 16, 2021
“To reduce the incidence of metastatic prostate cancer in the United States, we support policies that promote shared decision making to optimize PSA screening," said Vidit Sharma, MD.
February 10, 2021
In this interview, Emmanuel S. Antonarakis, MD, provides an overview of rucaparib (Rubraca) and olaparib (Lynparza), discusses the key trials that led to their approvals, and explains the urologist’s role in their use.
February 08, 2021
A streamline procedure allows treatment with the NanoTherm therapy system for focal ablation to be completed within 1 day.
“We continue to see a building story of benefit of statin medications in men who have prostate cancer,” says Robert J. Hamilton, MD, MPH.
Darolutamide is currently approved by the FDA for the treatment of men with nonmetastatic castration-resistant prostate cancer.